WO1995013068A1 - Composition medicamenteuse pour la circulation - Google Patents
Composition medicamenteuse pour la circulation Download PDFInfo
- Publication number
- WO1995013068A1 WO1995013068A1 PCT/JP1994/001898 JP9401898W WO9513068A1 WO 1995013068 A1 WO1995013068 A1 WO 1995013068A1 JP 9401898 W JP9401898 W JP 9401898W WO 9513068 A1 WO9513068 A1 WO 9513068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetra
- moranolin
- compound
- butenyl
- acetyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- R 1 is hydrogen, alkyl, acyl, carboxyalkyl.Alkoxycarbonyl, alkyloxy, hydroxyalkyl, cycloalkyl, alkyl, alkyl, alkyl, alkenyl, hydroxyalkylalkyl , Represents arylalkyl, aryloxyalkenyl, aryloxy, alkenyl, or benzylalkyl.
- R 2 , R 3 , R 4 and R s are the same or different and represent hydrogen, alkenyl, alkenyl, or syl (provided that all of R 2 , R 3 , R 4 and R 5 are hydrogen) Excluding those.)
- Organism has a mechanism that controls it against excessive fibrinolysis, plays a its central role is 2 - Brass Mi N'i down heat Bitter - is (under side of "a 2 -PI j) .
- a -PI has the function of temporarily inhibiting the action of plasmin in the blood, preventing the dissolution of the hemostatic plug, and stabilizing the thrombus by being taken into the hemostatic plug.
- a 2 - PI is increased after surgery as a kind of acute phase protein, has become one of the causes of post-operative thrombosis.
- alkyloxycarboxyalkyl for R 1 examples include, for example, methoxycarbonylmethyl, 2-methoxycarbonylyl, 2-methoxycarbonyl ⁇ -pill, 3-methoxycarbonylpropyl, and 2-methoxycarbonylpropyl.
- Methoxycarbonylbutyl, 3-methoxycarbonylbutyl, 4-methoxycarbonylbutyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, 2-ethoxycarbonylpropyl, 3-ethoxycarbonylpropyl, 2 -Ethoxycarbonylbutyl, 3-ethoxycarbonylbutyl, 4-ethoxycarbonylpropyl and the like can be mentioned.
- Those having a larger carbon number of alkyl are also included in the compounds of the present invention.
- Examples of the cycloalkylalkyl relating to R 1 include those having 3 to about carbon atoms; about L 0. For example, cyclopropylmethyl, cyclobutylmethyl, cyclopentyl J-methyl, cyclohexylylmethyl and the like can be mentioned. Those having a larger number of carbon atoms in the alkyl are also included in the compounds of the present invention. Examples of the arylalkyl for R 1 include those having about 7 to 20 carbon atoms.
- aryloxyalkyl for R 1 examples include those having about 7 to 21 carbon atoms.
- alkenyl for R 1 examples include straight-chain or branched ones having about 2 to 20 carbon atoms.
- alkenyl for R 1 examples include straight-chain or branched ones having about 2 to 20 carbon atoms.
- Examples thereof include 2-propenyl, 1-methyl-1-propenyl, trimethyl-2-propenyl, tert-butenyl, geranyl, and farnesyl. Those having a larger number of carbon atoms are also included in the compounds of the present invention.
- Examples of the hydroxy alkenyl of R 1 include, for example, 1-hydroxyvinyl, 2-hydroxy ⁇ -oxyvinyl, 1-hydroxy-1-propenyl, and 2-hydroxy-1-propenyl. , 3-Hydroxy-1-prodenyl, 1-Hydroxy-2-B-succinyl, 2-Hydroxy-2-propenyl, 3-Hydroxy-2-p-pi-nil, 1-Hydroxy-2-butenyl, 2-Hydroxy-2-butenyl, 3-Hydroxy-2-butenyl, 4-Hydroxy-2-butenyl, 1-Hydroxy-2-butenyl, 2-Hydroxy De Doxy-3-butenyl, 3-hydroxy-3-butenyl, 4-hydroxy-3-butenyl and the like. Wear. Those having a larger number of carbon atoms are also included in the compounds of the present invention.
- aryl alkenyl relating to R 1 include those having about 8 to 20 carbon atoms.
- aryloxyalkenyl related to R 1 examples include those having about 8 to 20 carbon atoms.
- the aryloxy alkenyl for R 1 includes those having about 14 to 25 carbon atoms.
- alkyl rubamoyl alkyl relating to R 1 examples include those having about 3 to 20 carbon atoms.
- Those having a larger number of carbon atoms are also included in the compounds of the present invention.
- alkyl related to R 2 , R 3 , R 4 , and R 5 may be the same or different and include straight-chain or branched ones having about 1 to 10 carbon atoms.
- lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, middle alkyl such as pentyl, isopentyl, hexyl and isohexyl, And lower alkyl such as decyl.
- lower alkyl such as methyl, ethyl, propyl, isoppi-pill, butyl, and isobutyl are preferred.
- alkenyl for R 2 , R 3 , R 4 and R 5 the same or different alkenyl having about 2 to 20 straight or branched carbon atoms can be mentioned.
- vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 2-methyl-2- Propenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, tert-butenyl, gerael, pharmacol and the like can be mentioned.
- Those having a larger number of carbon atoms are also included in the compounds of the present invention.
- R 5 , R 7 , R 8 , and R 9 represent the same silyl group having 1 to 8 carbon atoms.
- R 6 , R ′′ 7 , R 8 , and R 3 examples include holmil, rycetyl, propionyl, isopropionyl, butyri J, isobutyrinole, Parelli J, Isono Riri Re, Pinot, Mouth Iri, Hexanoyl, Octanol, Roil (Penzol, Toluoil, etc.), Acc Liloyl, methacrylyl, oxyl, methoxalyl, ethoxylyl, cyclohexylcarbonyl, halogeno (futsuig, chloride, bromide, iodide) benzylcarbonyl, Penziloxycarbonyl, hydroxycarbonyl, phenylethylcarbonyl, methylmalonyl, ethylmalonyl, propylmalonol and the like can be mentioned.
- physiologically acceptable salts include hydrochloride, nitrate, sulfate, and bromate.
- Inorganic acid salts such as salts and phosphates, acetates, succinates, fumarates, maleates, linates, lactates, tartrates, methansulfonates, tosylates And the like, organic salts, potassium salts, sodium salts, ammonium salts, and quaternary salts.
- N-CP- (2-trimethylammonioethoxy) cinnamoyl] Morano Lin hydrochloride The compound of the present invention can be produced by a known method as shown in JP-A-2-172975.
- moranolin is subjected to N-alkylation, N-sylation and the like by a conventional method (Japanese Patent Application Laid-Open No. 1-250350, etc.), Before or after, the compound can be produced by 0-alkylation, 0-tosylation, or the like of a free-drilling hydroxy group.
- the compound of the present invention When the compound of the present invention is administered as a drug, it can be applied in combination with or mixed with the drug to be administered simultaneously.
- the compound of the present invention is used as such or in a pharmaceutically acceptable non-toxic and inert carrier, for example, as a pharmaceutical composition having 10% to 95%, preferably 50% to 90%, animals including humans. Is administered.
- the carrier one or more solid, half-face or liquid diluents, fillers, and other prescription auxiliaries are used.
- the pharmaceutical compositions are preferably administered in dosage unit forms.
- the pharmaceutical composition of the present invention can be administered by injection, intra-tissue administration, topical administration (such as transdermal administration), or rectally. Of course, they are administered in dosage forms suitable for these administration methods. For example, oral administration and intra-tissue administration, particularly oral administration, are preferred.
- solid or liquid dosage units such as powders, capsules, tablets, dragees, granules, powders, suspensions, solutions, syrups, drops, sublingual tablets, etc. This can be done depending on the dosage form.
- Powders are prepared by comminuting the active substance to an appropriate degree. Powders are prepared by comminuting the active substance to a suitable fineness and then mixing with a similarly comminuted pharmaceutical carrier such as starch, edible carbohydrates such as mannitol, and the like. If necessary, flavoring agents, preservatives, dispersing agents, coloring agents, flavors and the like may be added.
- a similarly comminuted pharmaceutical carrier such as starch, edible carbohydrates such as mannitol, and the like.
- flavoring agents, preservatives, dispersing agents, coloring agents, flavors and the like may be added.
- Force capsules are prepared by first filling powdered powders, powders or granules as described in the section on tablets as described above into a force capsule outer shell such as a gelatin capsule. It is manufactured by Lubricants and glidants, such as colloidal silica, talc, magnesium stearate, calcium stearate, and solid polyethylene glycol It is also possible to mix the mixture into the state and then carry out the filling operation afterwards. Disintegrants and solubilizers such as carboxymethyl cellulose, carboxymethyl) recellulose calcium. Calcium carbonate, The addition of sodium carbonate can improve the efficacy of the drug when the capsule is taken.
- the fine powder of this product can be suspended and dispersed in vegetable oil, polyethylene glycol, glycerin, and a surfactant, and wrapped with gelatin sheet to form a soft capsule.
- Tablets are manufactured by adding a filler to form a powder mixture, granulating or slugging, then adding a disintegrant or lubricant and compressing.
- the powder mixture may be obtained by mixing the appropriately powdered substance with the above-mentioned diluents and pastes and, if necessary, binding agents (eg, carboxymethyl cellulose sodium, methylcellulose, hydroxypropyl J).
- Remethyl cellulose, gelatin, polyvinylpyrrolidone, polyvinyl alcohol, etc.), dissolution retardants (eg, paraffin), resorbents (eg, quaternary salts) and adsorbents (eg, benzene) Tonite, kaolin, dicalcium phosphate, etc.) may also be used in combination.
- the powder mixture is first moistened with a binder, for example, syrup, starch paste, rubbing rubber, a cellulose solution or a polymer solution, mixed with stirring, dried and pulverized into granules. be able to.
- a binder for example, syrup, starch paste, rubbing rubber, a cellulose solution or a polymer solution
- the drug should not go through the granulation / slagging process as described above.
- tableting may be performed directly after mixing with a fluid inert carrier.
- Other oral dosage forms that may also be used, such as a transparent or translucent protective coating consisting of a hermetic shell coating, a coating of sugar molecular material, and a wax topcoat, for example Solutions, chips, elixirs, and the like can also be presented in dosage unit form so that a given quantity contains a fixed amount of the drug.
- Ships are prepared by dissolving the compound in an appropriate aqueous flavor solution, and elixirs are prepared by using a non-toxic alcoholic carrier.
- Suspensions are formulated by dispersing the compound in a non-toxic carrier.
- FIG. 1 shows the ⁇ 2- ⁇ inhibitory activity of compound B and compound A. ⁇ time (time) and the vertical axis when the 1005 ⁇ 0 h alpha 2 -.
- the PI inhibitory activity (representing the S ⁇ Koh down DOO port Lumpur result, violence is the result of compound B, ⁇ represents the result of compound A, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95900281A EP0733364A4 (en) | 1993-11-12 | 1994-11-10 | MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28309093 | 1993-11-12 | ||
JP5/283090 | 1993-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995013068A1 true WO1995013068A1 (fr) | 1995-05-18 |
Family
ID=17661092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001898 WO1995013068A1 (fr) | 1993-11-12 | 1994-11-10 | Composition medicamenteuse pour la circulation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0733364A4 (ja) |
WO (1) | WO1995013068A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036757A1 (en) * | 1997-02-21 | 1998-08-27 | Nippon Shinyaku Co., Ltd. | Remedy for peptic ulcer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01250350A (ja) * | 1987-12-09 | 1989-10-05 | Nippon Shinyaku Co Ltd | 循環器用剤 |
WO1993015098A1 (en) * | 1992-01-31 | 1993-08-05 | Nippon Shinyaku Co., Ltd. | Lewis-type sugar chain derivative |
WO1994004546A1 (en) * | 1992-08-14 | 1994-03-03 | Nippon Shinyaku Co., Ltd. | Moranoline derivative |
-
1994
- 1994-11-10 WO PCT/JP1994/001898 patent/WO1995013068A1/ja not_active Application Discontinuation
- 1994-11-10 EP EP95900281A patent/EP0733364A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01250350A (ja) * | 1987-12-09 | 1989-10-05 | Nippon Shinyaku Co Ltd | 循環器用剤 |
WO1993015098A1 (en) * | 1992-01-31 | 1993-08-05 | Nippon Shinyaku Co., Ltd. | Lewis-type sugar chain derivative |
WO1994004546A1 (en) * | 1992-08-14 | 1994-03-03 | Nippon Shinyaku Co., Ltd. | Moranoline derivative |
Non-Patent Citations (1)
Title |
---|
See also references of EP0733364A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036757A1 (en) * | 1997-02-21 | 1998-08-27 | Nippon Shinyaku Co., Ltd. | Remedy for peptic ulcer |
Also Published As
Publication number | Publication date |
---|---|
EP0733364A1 (en) | 1996-09-25 |
EP0733364A4 (en) | 1998-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2157203C2 (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза | |
EP0250023B1 (en) | Nitrofurantoin dosage form | |
CA2323849C (en) | Orally administrable solid ribavirin dosage forms and process for making them | |
SK10822001A3 (sk) | Liek na liečenie vysokého krvného tlaku | |
US4666919A (en) | Stabilized pharmaceutical composition containing an isocarbostyril derivative | |
JPH0651625B2 (ja) | 高脂質血症治療剤 | |
CA2656270A1 (en) | Solid dose formulations of a thrombin receptor antagonist | |
WO2002087578A1 (fr) | Agent therapeutique pour rhumatisme articulaire chronique | |
CZ322794A3 (en) | Pharmaceutical preparation for inhibiting myeloperoxidase activity | |
CA2321369C (en) | Dosing regimens for lasofoxifene | |
JP2722220B2 (ja) | ピペリジノアルカノール誘導体の製剤組成物 | |
US6333361B1 (en) | Pharmaceutical composition containing zafirlukast | |
WO1995013068A1 (fr) | Composition medicamenteuse pour la circulation | |
EP0012621B1 (en) | Analgesic composition comprising acetaminophen as a potentiating agent | |
MY160429A (en) | 2, 5-disubstituted 3-mercaptopentanoic acid | |
EA006382B1 (ru) | Способ лечения заболевания хронической закупорки легочных путей | |
US6372763B1 (en) | Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI) | |
WO2007060976A1 (ja) | 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物 | |
JPH10226644A (ja) | 医薬組成物 | |
JPH0791273B2 (ja) | ベンズイミダゾール誘導体薬剤組成物 | |
JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
US3821381A (en) | Method of treatment | |
US3824315A (en) | Method of treatment | |
US3928602A (en) | Substituted phenoxymalonic acids, esters thereof and hypolipaemic agents containing the same for lowering lipid levels | |
WO1999051623A1 (en) | DEPRESSANT FOR PRODUCTION OF TGF-$g(b) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 648071 Date of ref document: 19960510 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995900281 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995900281 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995900281 Country of ref document: EP |